Plain-English translation of NCT06696742 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining Tislelizumab (an immunotherapy medication) with Clostridium butyricum (a probiotic supplement containing beneficial bacteria) can help treat bladder cancer more effectively. The study has two pathways: one for people receiving treatment before surgery to shrink tumors, and one for people receiving treatment after surgery to prevent cancer from returning. Researchers believe the bacteria supplement may help the immunotherapy work better.
Current immunotherapy treatments don't work well enough for all bladder cancer patients. This trial is exploring whether adding a natural probiotic supplement might strengthen the immune system's ability to fight cancer cells and improve overall outcomes.
You likely qualify if…
You likely don't qualify if…
If you join the pre-surgery group, you'll receive chemotherapy infusions and immunotherapy infusions every three weeks for three cycles, plus take probiotic tablets twice daily. If you join the post-surgery group, you'll receive immunotherapy infusions every three weeks for 1–2 years and take the probiotic tablets twice daily. The study will monitor how well the treatment works and track any side effects through regular clinic visits and tests.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~60 participants
Started
February 2024
Primary completion
February 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiao Yang
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.